FOXM1 and breast cancer: FOXM1 expression was determined by immunohistochemical analysis of biopsies obtained from three patients with advanced breast cancer enrolled in the POSEIDON phase Ib trial, which was designed to assess the efficacy of treatment with GDC-0032 plus tamoxifen (Baird et al., 2019) (Figure 8A).